Pfizer: mixed data from obesity trial

(CercleFinance.com) - Pfizer announces initial data from the Phase 2b clinical trial of its oral GLP-1RA drug candidate danuglipron in obese adults without type 2 diabetes, which met its primary endpoint.


It demonstrated a statistically significant change in body weight from baseline, with placebo-adjusted mean weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks.

Although the most frequent adverse events were mild and gastrointestinal in nature, consistent with the mechanism, high rates of adverse events were observed, Pfizer points out, citing high discontinuation rates of over 50%.

The ongoing pharmacokinetic study of the daily formulation of danuglipron will continue, the results of which will inform the way forward. As things stand, it will not proceed to Phase 3 studies.


Copyright (c) 2023 CercleFinance.com. All rights reserved.